Skip to content
Screener

Insulet PODD Total Liabilities & Equity

Total Liabilities & Equity at other companies

Eli Lilly logo
Eli LillyLLY
$142.28B+41.0%
Tandem Diabetes Care logo
Tandem Diabetes CareTNDM
$1.15B+31.8%
Medtronic logo
MedtronicMDT
$93.03B+1.5%
Beta Bionics logo
Beta BionicsBBNX
$292.39M-11.4%
Embecta Corp. logo
Embecta Corp.EMBC
$1.03B-8.1%
Opko Health logo
Opko HealthOPK
$1.83B-7.3%

Other financials

Income statement

See full
Revenue$801.7M+23.5%
Gross profit$562.6M+24.4%
Operating income$129.7M+7.1%
Net income$95.0M+322%
EPS (diluted)$1.37+328%

Balance sheet

See full
Cash & equivalents$534.9M-52.3%
Total debt$974.7M-47.6%
Total equity$1.4B-2.8%
Total assets$3.2B-8.8%

Cash flow

See full
Operating cash flow$88.4M-55.0%
CapEx$32.5M+74.7%
Free cash flow$55.9M-68.6%

Valuation

See full
Market cap$9.23B-52.7%
Enterprise value$9.67B-52.3%
P/E24.6×-58.1×
P/S-5.2×

Profitability

See full
Gross margin71.1%+0.3pp
Operating margin16.9%-0.4pp
Net margin12.3%+2.3pp
FCF margin9.6%-7.5pp

Returns & leverage

See full
Return on equity26%+6.8pp
Debt / equity0.7×-0.6×
Current ratio2.5×+0.2×

Where this comes from

Reported directly by Insulet in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.

The source filing: Insulet’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:06 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001145197-26-000169
(in millions, except share and per share data)June 30, 2026December 31, 2025
Common stock, $0.001 par value,100,000,000 authorized; 70,798,932 and 70,588,192 issued0.10.1
Additional paid-in capital1,309.01,274.9
Accumulated earnings473.5287.4
Accumulated other comprehensive income1.912.5
Treasury stock, at cost; 1,447,918 and 197,374 shares(363.5)(60.4)
Deferred compensation1.20.8
Total stockholders’ equity1,422.21,515.2
Total liabilities and stockholders’ equity$3,165.1$3,190.4

Item 1. Condensed Consolidated Financial Statements (Unaudited)

FAQ

What is Insulet's total liabilities & equity?
Insulet (PODD) reported total liabilities & equity of $3.17B in Q2 2026.
How has Insulet's total liabilities & equity changed year-over-year?
Insulet's total liabilities & equity decreased by 8.8% year-over-year, from $3.47B to $3.17B.
What is the long-term trend for Insulet's total liabilities & equity?
Over 5 years (2020 to 2025), Insulet's total liabilities & equity has grown at a 11.2% compound annual growth rate (CAGR), from $1.87B to $3.19B.
What does total liabilities & equity mean?
Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.

Ask your AI about Insulet's total liabilities & equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude